{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:41Z","timestamp":1787020241185,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the management of LAPC. Clinical outcomes and safety were assessed for S-1 plus concurrent radiotherapy (S-1\u2009+\u2009RT) and gemcitabine plus nab-paclitaxel (GnP) in patients with LAPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pooled exploratory analysis of individual patient data derived from two multi-institutional randomized phase II trials conducted by the Japan Clinical Oncology Group (JCOG1106 and JCOG1407). JCOG1106 evaluated S-1\u2009+\u2009RT with or without induction chemotherapy. JCOG1407 compared GnP with modified FOLFIRINOX. Based on the results of these trials, S-1\u2009+\u2009RT and GnP were selected as promising regimens for chemoradiotherapy and systemic chemotherapy, respectively. The primary endpoint of this study was progression-free survival (PFS). Inverse probability of treatment weighting (IPTW) with stabilized weights was applied based on the propensity score to account for baseline imbalances between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 113 patients were included. After adjustment for patient characteristics, Kaplan\u2013Meier curves showed median PFS, overall survival (OS), and distant metastasis-free survival (DMFS) of 10.2 vs. 9.3 (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.60\u20131.30), 19.1 vs. 21.2 (HR, 0.73; 95% CI, 0.48\u20131.11), and 11.5 vs. 13.1 months (HR, 0.73; 95% CI, 0.49\u20131.08) for S-1\u2009+\u2009RT and GnP, respectively. Treatment received after protocol therapy differed substantially: 77.5% in the S-1\u2009+\u2009RT group received single-agent chemotherapy, whereas 50.0% in the GnP group, received more intensive regimens, including multi-agent chemotherapy or chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GnP may offer advantages in suppressing micrometastatic disease, whereas S-1\u2009+\u2009RT may provide benefits in local disease control. These findings suggest that both approaches represent important and complementary therapeutic options for LAPC. Prospective randomized studies are warranted to determine the optimal initial strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15699-8","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:54:30Z","timestamp":1770717270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)"],"prefix":"10.1186","volume":"26","author":[{"given":"Yusuke","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Hisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"3","key":"15699_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"15699_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"issue":"2","key":"15699_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jjco\/hyaa198","volume":"51","author":"T Ioka","year":"2021","unstructured":"Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, et al. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan clinical oncology group trial, JCOG1106. Jpn J Clin Oncol. 2021;51(2):235\u201343.","journal-title":"Jpn J Clin Oncol"},{"key":"15699_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2023","unstructured":"Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135\u201344.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15699_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4143\/crt.2015.226","volume":"48","author":"Y Choi","year":"2016","unstructured":"Choi Y, Oh DY, Kim K, Chie EK, Kim TY, Lee KH, et al. Concurrent chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: A retrospective cohort study. Cancer Res Treat. 2016;48(3):1045\u201355.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"15699_CR6","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.3390\/curroncol30060427","volume":"30","author":"A Arcelli","year":"2023","unstructured":"Arcelli A, Tarantino G, Cellini F, Buwenge M, Macchia G, Bertini F, et al. Comparative effectiveness of chemotherapy alone versus Radiotherapy-Based regimens in locally advanced pancreatic cancer: A Real-World multicenter analysis (PAULA-1). Curr Oncol. 2023;30(6):5690\u2013703.","journal-title":"Curr Oncol"},{"issue":"1","key":"15699_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12876-023-02739-x","volume":"23","author":"ZM Wang","year":"2023","unstructured":"Wang ZM, Ma HB, Meng Y. Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis. BMC Gastroenterol. 2023;23(1):107.","journal-title":"BMC Gastroenterol"},{"issue":"25","key":"15699_CR8","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"398","key":"15699_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","volume":"82","author":"PR Rosenbaum","year":"1987","unstructured":"Rosenbaum PR. Model-Based direct adjustment. J Am Stat Assoc. 1987;82(398):387\u201394.","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"15699_CR10","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242\u201358.","journal-title":"Stat Med"},{"issue":"1","key":"15699_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","volume":"75","author":"SR Cole","year":"2004","unstructured":"Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45\u20139.","journal-title":"Comput Methods Programs Biomed"},{"issue":"28","key":"15699_CR12","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"2","key":"15699_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361.","journal-title":"Pharm Stat"},{"issue":"387","key":"15699_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. J Am Stat Assoc. 1984;79(387):516\u201324.","journal-title":"J Am Stat Assoc"},{"issue":"17","key":"15699_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA. 2016;315(17):1844\u201353.","journal-title":"JAMA"},{"issue":"10","key":"15699_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"15699_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395.","journal-title":"J Clin Invest"},{"issue":"7547","key":"15699_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint Blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"key":"15699_CR19","doi-asserted-by":"crossref","unstructured":"Fujiwara K, Saung MT, Jing H, Herbst B, Zarecki M, Muth S, et al. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. J Immunother Cancer. 2020;8(2):1\u201310.","DOI":"10.1136\/jitc-2019-000351"},{"issue":"2","key":"15699_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15252\/emmm.201606674","volume":"9","author":"A Azad","year":"2017","unstructured":"Azad A, Yin Lim S, D\u2019Costa Z, Jones K, Diana A, Sansom OJ, et al. PD-L1 Blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017;9(2):167\u201380.","journal-title":"EMBO Mol Med"},{"issue":"11","key":"15699_CR21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/jjco\/hyae084","volume":"54","author":"Y Sano","year":"2024","unstructured":"Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, et al. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with\/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). Jpn J Clin Oncol. 2024;54(11):1214\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"10409","key":"15699_CR22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"key":"15699_CR23","doi-asserted-by":"crossref","unstructured":"Reni M, Macchini M, Orsi G, Procaccio L, Malleo G, Carconi C, et al. Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2\u2009\u00d7\u20092 factorial phase 3 trial. Lancet. 2025;406(10522):2945\u201356.","DOI":"10.1016\/S0140-6736(25)01685-X"},{"issue":"21","key":"15699_CR24","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO-25-00746","volume":"43","author":"HM Babiker","year":"2025","unstructured":"Babiker HM, Picozzi V, Chandana SR, Melichar B, Kasi A, Gang J, et al. Tumor treating fields with gemcitabine and Nab-Paclitaxel for locally advanced pancreatic adenocarcinoma: Randomized, Open-Label, pivotal phase III PANOVA-3 study. J Clin Oncol. 2025;43(21):2350\u201360.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15699-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:01:05Z","timestamp":1781632865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15699"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15699-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the precepts established in the Declaration of Helsinki and Ethical Guidelines for Medical and Biological Research Involving Human Subjects. This study was approved by the Institutional Review Board of National Cancer Center on April 1, 2025 (2024\u2009\u2212\u2009342). The requirement for individual consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.M. received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, and Merck. His spouse is an employee of Pfizer. T.I. received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., and Novartis Pharma K.K. J.F. received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, Astra Zeneca, Servier, MSD, Novartis, Takeda Pharmaceutical, Taiho Pharmaceutical, Teijin, Daiichi Sankyo, Ohhara Pharmaceutical, J-Pharma, Astellas, Delta-Fly-Pharma, TME Therapeutics, Pfizer, Onco Therapy Science, and Incyte Biosciences, and consulting fees from J-Pharma, participated on a Data Safety Monitoring Board or Advisory Board for Onco Therapy Science, Chugai Pharmaceutical, and Taiho Pharmaceutical, and held a leadership role in the Japan Oncology Network in Hepatobiliary and Pancreas. S.K. received lecture fees from Chugai Pharmaceutical Co., Ltd, and Eisai, and honoraria from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Eisai, MSD, K.K., Nihon Servier Co., Ltd., Novartis, Ohtsuka Pharmaceutical, Ono Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. H.F. received lecture fees from Chugai Pharmaceutical Co., Ltd, Kyowa Kirin Co., Ltd, and CMIC Co., Ltd. T.O. received grants from AstraZeneca, Syneos, Incyte, CHIOME Bioscience Inc., Sysmex Corporation, Amgen Inc. ,Linical, and Labcorp Genetics, consulting fees from AstraZeneca, Eisai, Nihon Medi-Physics Co., Ltd, Amgen Inc., Jazz Pharmaceuticals, and OHARA Pharmaceutical Co., Ltd., and honoraria from MSD, K.K., Eisai, Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Servier Co., Ltd., Chugai Pharmaceutical Co., Ltd., Johnson & Johnson K.K., AstraZeneca, Kyowa Kirin, and Novartis. M.I. received honoraria from Guardant Health Japan, Nihon Servier Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K, Nippon Kayaku Co., Ltd., and Yakult Honsha Co., Ltd., and research funding from Boehringer Ingelheim GmbH, Delta-Fly-Pharma, Merus N.V, Labcorp Genetics, Nihon Servier Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amgen Inc., and Novartis. N.S. received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, MSD K.K, Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. K.O. received honoraria from AstraZeneca, K.K, Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., and MSD K.K. K.Y. received honoraria from Chugai Pharmaceutical, Daiichi Sankyo, Yakult Honsha, Takeda, Merck Serono, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical, MSD, and Bristol-Myers Squibb, and received research funding from Taiho Pharmaceutical. M.K. owns stocks in Therabiopharma Inc. and received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca, K.K, and MSD K.K. T.Y. received grants from AstraZeneca, KK, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., and honoraria from AstraZeneca, KK, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Bristol-Myers Squibb, AbbVie, and Gilead Sciences. Y.K. received grants from AstraZeneca, Syneos, Incyte, Sysmex Corporation, Amgen Inc. Labcorp Genetics, Eisai, Amgen Inc., Jazz Pharmaceuticals, honoraria from MSD, Eisai, Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Servier Co., Ltd., Chugai Pharmaceutical Co., Ltd., BMS, Merck, Astellas. N.F. received lecture fees from AstraZeneca K.K. and Novartis Pharma K.K. S.S. received grants from AstraZeneca K.K., Delta-Fly Pharma, INC., Nihon Servier, Co., Ltd., and Taiho Pharmaceutical Co., Ltd. M.U. received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, Yakult Honsha Co., Ltd., MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K., and received research funding from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, Eisai Co., Ltd., Novartis Pharma K.K, Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta Fly Pharma), Inc., Amgen Inc., and Chiome Bioscience Inc. Y.S., R.K., M.O., S.N., Y.I., H.M., F.N., K.H., Y.T., N.H., K.K., T.H., K.T., and S.M. declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}